Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
14.15
+0.07 (0.50%)
At close: Aug 26, 2026, 4:00 PM EDT
14.15
0.00 (0.00%)
After-hours: Aug 26, 2026, 7:30 PM EDT
Enanta Pharmaceuticals Revenue
Enanta Pharmaceuticals had revenue of $14.36M in the quarter ending June 30, 2026, a decrease of -21.60%. This brings the company's revenue in the last twelve months to $65.26M, up 0.70% year-over-year. In the fiscal year ending September 30, 2025, Enanta Pharmaceuticals had annual revenue of $65.32M, down -3.42%.
Revenue (ttm)
$65.26M
Revenue Growth
+0.70%
P/S Ratio
6.32
Revenue / Employee
$543,817
Employees
120
Market Cap
412.12M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 65.32M | -2.31M | -3.42% |
| Sep 30, 2024 | 67.64M | -11.57M | -14.61% |
| Sep 30, 2023 | 79.20M | -6.96M | -8.07% |
| Sep 30, 2022 | 86.16M | -10.91M | -11.24% |
| Sep 30, 2021 | 97.07M | -25.40M | -20.74% |
| Sep 30, 2020 | 122.47M | -82.72M | -40.31% |
| Sep 30, 2019 | 205.20M | -1.43M | -0.69% |
| Sep 30, 2018 | 206.63M | 103.81M | 100.97% |
| Sep 30, 2017 | 102.81M | 14.55M | 16.48% |
| Sep 30, 2016 | 88.27M | -72.61M | -45.13% |
| Sep 30, 2015 | 160.88M | 113.14M | 236.98% |
| Sep 30, 2014 | 47.74M | 15.69M | 48.94% |
| Sep 30, 2013 | 32.05M | -9.65M | -23.15% |
| Sep 30, 2012 | 41.71M | -176.00K | -0.42% |
| Sep 30, 2011 | 41.88M | 19.12M | 83.99% |
| Sep 30, 2010 | 22.76M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Fennec Pharmaceuticals | 59.22M |
| vTv Therapeutics | 36.84M |
| Foghorn Therapeutics | 36.74M |
| X4 Pharmaceuticals | 15.85M |
| Upstream Bio | 3.16M |
| EyePoint | 2.79M |
ENTA News
- 16 days ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 - Business Wire
- 16 days ago - Enanta Pharmaceuticals Earnings release: Q3 2026 - Filings
- 16 days ago - Enanta Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 2 months ago - Enanta announces European Commission approval of Maviret - TheFly
- 2 months ago - Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - Business Wire
- 2 months ago - Enanta to advance zelicapavir into registrational Phase 2b/3 clinical trial - TheFly
- 2 months ago - Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV) - Business Wire
- 2 months ago - Enanta Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts